FDC LTD.

FDC Ltd has announced a Board of Directors meeting scheduled for October 27, 2026. The primary agenda items include the consideration and approval of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the auditors' limited review reports. Additionally, the Board will consider and potentially approve a proposal for the buyback of the company's fully paid-up equity shares through the tender offer route. The buyback terms, including size and price, will be subject to regulatory approvals and applicable laws. The trading window remains closed for designated persons until 48 hours after the financial results are declared.

FDC Ltd has announced the closure of its trading window for designated persons and their relatives from October 1, 2026. This closure will remain in effect until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The company will announce the date of the board meeting to consider these financial results in due course.

FDC Ltd has issued a corrigendum to its 86th Annual General Meeting (AGM) notice for FY 2025-26, rectifying a typographical error concerning the e-voting cutoff date. The correct cutoff date for e-voting is now September 17, 2026, revised from the previously stated September 16, 2026. Consequently, the book closure period has been adjusted to September 18, 2026, through September 23, 2026, inclusive. All other details in the original AGM notice remain unchanged. The company will publish this corrigendum in newspapers and forward it to the stock exchanges for shareholder information.

Nandan Mohan Chandavarkar has filed a disclosure under SEBI (SAST) Regulations, 2011, detailing a change in his shareholding in FDC Limited. The transaction, an off-market inter-se transfer by way of gift without consideration, occurred on June 24, 2026. Prior to the transaction, his holding was 50,41,086 shares (3.10% of total capital). After the transaction, his direct holding is 11,000 shares (0.01%). The disclosure also covers holdings of associated trusts and other promoter group members, indicating a shift in direct and indirect control within the promoter group.

FDC Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report details the company's commitment to environmental, health, and safety standards, including medical assistance and periodic health checkups for employees. FDC Ltd confirms there are no significant orders from regulators or courts that would impact its going concern status. The company also expressed gratitude to its stakeholders, including employees, government authorities, financial institutions, and the medical fraternity, for their continued support and cooperation.

FDC Ltd has released its Annual Report for the financial year 2025-26, in compliance with SEBI Listing Regulations. The report is accessible on the company's website. The 86th Annual General Meeting (AGM) is scheduled for Thursday, September 24, 2026, at 10:00 a.m. IST, to be held through Video Conferencing/Other Audio-Visual Means. The cut-off date for determining members eligible to vote on AGM resolutions is Wednesday, September 16, 2026. Remote e-voting will be open from Monday, September 21, 2026, at 09:00 a.m. IST, until Wednesday, September 23, 2026, at 05:00 p.m. IST. The report outlines the company's strategic vision, commitment to wellness, and corporate governance, including changes in board and key managerial personnel.

FDC Ltd has announced the details for its 86th Annual General Meeting (AGM) for the financial year 2025-26. The AGM will be held on Thursday, September 24, 2026, at 10:00 a.m. IST via Video Conferencing/Other Audio-Visual Means. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY 2025-26, the re-appointment of Executive Director Mr. Ashok Anand Chandavarkar, and the ratification of remuneration for the Cost Auditor, M/s. GMVP & Associates LLP, for FY 2026-27. The cut-off date for determining voting eligibility is September 16, 2026, with remote e-voting available from September 21 to September 23, 2026. The Annual Report for FY 2025-26 is also available on the company's website.

FDC Ltd has received an interim stay from the High Court of Delhi concerning a notice from FSSAI Maharashtra regarding the seizure of stock. The court has granted the company eight months to exhaust its existing stock labeled 'electrolyte'/'electrolyte drink' and to update its product labels. FDC Ltd stated that this development has no material adverse impact on its financials, operations, or other activities. The company had filed a writ petition seeking relief after the initial stock seizure.

FDC Ltd's subsidiary, FDC International Ltd., has secured Marketing Authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its Atropine 1.0% w/v Eye Drops, Solution. This approval allows the product to be marketed in the United Kingdom, marking a significant step for the company's international pharmaceutical presence and product portfolio expansion in the ophthalmic segment.

FDC Limited announced its unaudited financial results for Q1 FY27, reporting a 3.0% year-on-year increase in consolidated revenue from operations to ₹668 crores. EBITDA grew by 1.9% to ₹143 crores, while Profit Before Tax (PBT) and Profit After Tax (PAT) saw increases of 9.4% and 9.2% respectively. Earnings Per Share (EPS) rose to ₹8.14 from ₹7.45 in the prior year. The growth was primarily driven by strong performance in International Formulations, especially the US business, which surged 118.4%. Domestic Formulations and APIs experienced a slight decline. The company also received US FDA approval for Cefixime for Oral Suspension.